Since the delivery of our first ultra-widefield device in 2000, Optos has continued to gather clinical evidence about the importance of seeing the peripheral retina especially in patients with diabetes. optomap is the only ultra-widefield retinal imaging technology that captures up to 200° of the retina in a single image.
optomap is clinically validated and supported by over 550 completed and ongoing clinical studies.
optomap results are equal to ETDRS in all categories.1
optomap imaging demonstrates that diabetic lesions that occur outside of the ETDRS 7 standard fields predict increased risk of diabetic retinopathy progression over a 4 year period. 2
Ultra-widefield retinal evaluation provides information that is necessary to completely assess the risk of DR progression.3
1,2,3 - Data on file